Combined Intralipid-urotherapy for Patients with Cancer: A Creative Review

References (103)

1. 1 A Cell Culture Model for T Lymphocyte Clonal Anergy [DOI]
2. 2 Progress in human tumour immunology and immunotherapy [DOI]
3. 3 Spontaneous Regression of Cancer [DOI]
4. 4 Significance of CD44 gene products for cancer diagnosis and disease evaluation [DOI]
5. 5 Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. [DOI]
6. 6 Overview of the Mucosal Immune System [DOI]
7. 7 Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. [DOI]
8. 8 Progress in the development of immunotherapy for the treatment of patients with cancer [DOI]
9. 9 ORIGINAL ARTICLE: Duration of Intralipid’s Suppressive Effect on NK Cell’s Functional Activity [DOI]
10. 10 New approaches to antibody therapy [DOI]
11. 11 Immunotherapy of Cancer: Regression of Tumors after Intralesional Injection of Living Mycobacterium bovis [DOI]
12. 12 Epidermal Growth Factor: Identification of a New Hormone in Human Urine [DOI]
13. 13 Inhibition of Specific Immune Responses by Feeding Protein Antigens [DOI]
14. 14 Polyamines in colorectal cancer. Evaluation of polyamine concentrations in the colon tissue, serum, and urine of 50 patients with colorectal cancer [DOI]
15. 15 An overview of cancer immunotherapy [DOI]
16. 16 Sensing Environmental Lipids by Dendritic Cell Modulates Its Function [DOI]
17. 17 Oral Immunization: Past and Present [DOI]
18. 18 A new era of cancer immunotherapy: converting theory to performance [DOI]
19. 19 Cumulative effects of age and pathology on plasma carcinoembryonic antigen in an unselected elderly population [DOI]
20. 20 Dendritic Cells for Specific Cancer Immunotherapy [DOI]
21. 21 Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms [DOI]
22. 22 Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein [DOI]
23. 23 Experimental vaccine strategies for cancer immunotherapy [DOI]
24. 24 Late Development of Primary Carcinoma of the Colon Following Ureterosigmoidostomy [DOI]
25. 25 Specificity of auto‐tumor cytotoxicity exerted by fresh, activated and propagated human t lymphocytes [DOI]
26. 26 Adenocarcinoma at the site of ureterosigmoidostomies for exstrophy of the bladder [DOI]
27. 27 Antibody Responses to Melanoma/Melanocyte Autoantigens in Melanoma Patients [DOI]
28. 28 Functional Studies of Peyer's Patches: Evidence for Their Participation in Intestinal Immune Responses [DOI]
29. 29 Autologous, hapten-modified vaccine as a treatment for human cancers.
30. 30 Cancer Immunotherapy Targeting WT1 Protein [DOI]
31. 31 Impediments to Successful Immunotherapy [DOI]
32. 32 Lymphoid depletion in ileal loops: Mechanism and clinical implications [DOI]
33. 33 T cell-based immunotherapy for cancer: a virtual reality? [DOI]
34. 34 Specific Targeting Immunotherapy of Cancer with Bispecific Antibodies. [DOI]
35. 35 Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL‐2 cDNA [DOI]
36. 36 Inhibition of specific immune responses by feeding protein antigens. II. Effects of prior passive and active immunization.
37. 37 Autoimmune and Antitumor Consequences of Antibodies Against Antigens Shared by Normal and Malignant Tissues [DOI]
38. 38 INNOVATIVE TREATMENTS FOR PANCREATIC CANCER [DOI]
39. 39 Urinary polyamine levels in patients with gastrointestinal malignancy [DOI]
40. 40 Inhibition of Immunoglobulin Synthesis In Vitro by Intravenous Lipid Emulsion (Intralipid) [DOI]
41. 41 DNA-based vaccines for the treatment of cancer – an experimental model [DOI]
42. 42 Using in silico transcriptomics to search for tumor-associated antigens for immunotherapy [DOI]
43. 43 Serum and Salivary Antibody Responses and the Development of Oral Tolerance after Oral and Intragastric Antigen Administration [DOI]
44. 44 Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture ? No correlation with the postsurgical clinical course [DOI]
45. 45 Tumour immunology: T cells work together to fight cancer [DOI]
46. 46 Gastric juice CEA levels: importance of age and gastric mucosal damage [DOI]
47. 47 DNA-Based Tumor Vaccines [DOI]
48. 48 Intralipid‐Based Short‐Term Total Parenteral Nutrition Does Not Impair Small Intestinal Mucosa‐Related Cellular Immune Reactivity in the Healthy Rat [DOI]
49. 49 TREATMENT OF GLOMERULONEPHRITIS BY ANTIGEN [DOI]
50. 50 [Telomerase, a universal target in immunotherapy strategies against tumor?].
51. 51 Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma [DOI]
52. 52 Gene Transfer into Humans — Immunotherapy of Patients with Advanced Melanoma, Using Tumor-Infiltrating Lymphocytes Modified by Retroviral Gene Transduction [DOI]
53. 53 Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. [DOI]
54. 54 Cancer/testis antigens: an expanding family of targets for cancer immunotherapy [DOI]
55. 55 Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations [DOI]
56. 56 IMMUNOLOGICAL ASPECTS OF MALIGNANT DISEASE [DOI]
57. 57 Current Developments in Cancer Vaccines and Cellular Immunotherapy [DOI]
58. 58 Interleukin-2 and interleukin-15: immunotherapy for cancer [DOI]
59. 59 Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans [DOI]
60. 60 Immunoregulatory T-Cell Pathways [DOI]
61. 61 Inhibition of S-antigen induced experimental autoimmune uveoretinitis by oral induction of tolerance with S-antigen. [DOI]
62. 62 Regression and inhibition of sarcoma growth by interference with a radiosensitive T-cell population. [DOI]
63. 63 Mature Dendritic Cell Generation Promoted by Lysophosphatidylcholine [DOI]
64. 64 Cancer vaccines and immunotherapy [DOI]
65. 65 Urinary Prostate Specific Antigen Levels: Role in Monitoring the Response of Prostate Cancer to Therapy [DOI]
66. 66 Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities [DOI]
67. 67 The Relation of Sex Hormones to Peptic Ulcer [DOI]
68. 68 Cancer immunoprevention: tracking down persistent tumor antigens [DOI]
69. 69 Adjuvant immunotherapy for solid tumors: from promise to clinical application [DOI]
70. 70 Development of vaccines against self-antigens: the p53 paradigm.
71. 71 Detection by monoclonal antibody of carbohydrate antigen CA 50 in serum of patients with carcinoma. [DOI]
72. 72 Combination Immunotherapy for Cancer:Synergistic Antitumor Interactions of Interleukin-2, Alfa Interferon, and Tumor-Infiltrating Lymphocytes [DOI]
73. 73 Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells [DOI]
74. 74 The generation of a ‘tolerogen’ after the ingestion of ovalbumin is time-dependent and unrelated to serum levels of immunoreactive antigen [DOI]
75. 75 Human tumor antigens: implications for cancer vaccine development [DOI]
76. 76 The effect of Intralipid on mononuclear and polymorphonuclear phagocytes [DOI]
77. 77 Colonic neoplasms complicating ureterosigmoidostomy [DOI]
78. 78 Genetic differences in immune exclusion and partial tolerance to ingested antigens.
79. 79 Genetic Immunotherapy for Cancer [DOI]
80. 80 Neoplasia at the Site of Ureterosigmoidostomy [DOI]
81. 81 Immunité anti-tumorale et thérapies cellulaires du cancer [DOI]
82. 82 New Cancer Therapy by Immunomanipulation [DOI]
83. 83 A soluble form of the adhesion receptor CD58 (LFA‐3) is present in human body fluids [DOI]
84. 84 Osteogenic sarcoma. Immunologic parameters before and during immunotherapy with tumor-specific transfer factor. [DOI]
85. 85 Colonic Neoplasms Following Ureterosigmoidostomy [DOI]
86. 86 Active immunization against cancer cells: impediments and advances.
87. 87 Antibody Production to the Factor in Human Urine Stimulating Colony Formation In Vitro by Bone Marrow Cells [DOI]
88. 88 Antigen‐Driven Peripheral Immune Tolerance [DOI]
89. 89 Comparison of 15 Monoclonal Antibodies against Tumor-Associated Antigens of Transitional Cell Carcinoma of the Human Bladder [DOI]
90. 90 Thrombopoiesis‐ and Megakaryocyte Colony‐stimulating Factors in the Urine of Patients with Idiopathic Thrombocytopenic Purpura [DOI]
91. 91 Oral tolerance in protein-deprived mice. II. Evidence of normal 'gut processing' of ovalbumin, but suppressor cell deficiency, in deprived mice.
92. 92 Cell‐mediated reactivity to antigens shared by moloney‐virus‐induced lymphomas (LSTRA) and certain 3‐methylcholanthrene‐induced mouse sarcomas [DOI]
93. 93 CA 50 Determination in body fluids: Can we screen patients at risk for gastric cancer? [DOI]
94. 94 Immunotherapy and genitourinary neoplasia.
95. 95 The effect of preoperative nutrition on the immune system [DOI]
96. 96 Intravascular lung macrophages play an essential role in lipid entrapment and the inflammatory tissue reaction seen after long-term lipid-based parenteral nutrition in pigs [DOI]
97. 97 Prognostic significance of urinary antigen analysis by enzyme-linked immunosorbent assay in melanoma patients.
98. 98 Cancer immunogene therapy.
99. 99 The emerging role of the dendritic cell in novel cancer therapies.
100. 100 Effect of Intralipid on the Phagocytic and Microbicidal Capacity of Human Monocytes in Culture [DOI]
101. 101 Immunotherapy for Colorectal Cancer [DOI]
102. 102 Tumor Immunology
103. 103 Malignant Tumors of the Small Bowel [DOI]

Cited by 0

No indexed citations yet.

Related research

• Does Pain Adversely Affect the Quality of Life in Hospitalized Cancer Patients? — shares topic coverage
• Complementary Medicine Intervention in Breast Cancer Patients with Pain — shares topic coverage
• Use of Performance Status Score for Cytotoxic Chemotherapy among Surgeons in a Tertiary Hospital, Southern Nigeria — shares topic coverage
• Breast Self Examination and Cancer Awareness among Female Staff in Federal Medical Center, Yenagoa, Bayelsa State (Knowledge and Practice) — shares topic coverage
• Assessment of Cancer Risk from Fluorscopic Bile Duct Examinations at Sanjiwani Hospital, Gianyar — shares topic coverage